Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Moderate to Severe Hidradenitis Suppurativa (Step-Up HS)
NCT05889182Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2023
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 37
01
Overview
A Phase 3 trial of upadacitinib in hidradenitis suppurativa (HS), sponsored by AbbVie Inc.. Started Jun 2023; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05889182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05889182.